Wall Street Praises Precision BioSciences Inc. (DTIL) After Recent Earnings Report – News Heater
Home  »  Companies   »  Wall Street Praises Precision BioSciences Inc. (DT...

Wall Street Praises Precision BioSciences Inc. (DTIL) After Recent Earnings Report

Precision BioSciences Inc. (NASDAQ:DTIL) went up by 10.32% from its latest closing price compared to the recent 1-year high of $14.38. The company’s stock price has collected 14.88% of gains in the last five trading sessions.

Is It Worth Investing in Precision BioSciences Inc. (NASDAQ :DTIL) Right Now?

Opinions of the stock are interesting as 6 analysts out of 10 who provided ratings for Precision BioSciences Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The average price from analysts is $10.56, which is $9.17 above the current price. DTIL currently public float of 55.65M and currently shorts hold a 5.41% ratio of that float. Today, the average trading volume of DTIL was 806.52K shares.

DTIL’s Market Performance

DTIL stocks went up by 14.88% for the week, with a monthly drop of -19.65% and a quarterly performance of -54.43%, while its annual performance rate touched -87.19%. The volatility ratio for the week stands at 9.91% while the volatility levels for the past 30 days are set at 12.36% for Precision BioSciences Inc. The simple moving average for the period of the last 20 days is -9.53% for DTIL stocks with a simple moving average of -77.56% for the last 200 days.

Analysts’ Opinion of DTIL

Many brokerage firms have already submitted their reports for DTIL stocks, with BMO Capital Markets repeating the rating for DTIL by listing it as a “Outperform.” The predicted price for DTIL in the upcoming period, according to BMO Capital Markets is $7 based on the research report published on June 17th of the current year 2022.

BTIG Research gave a rating of “Buy” to DTIL, setting the target price at $16 in the report published on July 27th of the previous year.

DTIL Trading at -27.76% from the 50-Day Moving Average

After a stumble in the market that brought DTIL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.33% of loss for the given period.

Volatility was left at 12.36%, however, over the last 30 days, the volatility rate increased by 9.91%, as shares sank -18.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -53.82% lower at present.

During the last 5 trading sessions, DTIL rose by +14.88%, which changed the moving average for the period of 200-days by -90.18% in comparison to the 20-day moving average, which settled at $1.5205. In addition, Precision BioSciences Inc. saw -81.22% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at DTIL starting from JANTZ DEREK, who sale 18,849 shares at the price of $2.06 back on Jun 08. After this action, JANTZ DEREK now owns 4,055,174 shares of Precision BioSciences Inc., valued at $38,829 using the latest closing price.

Scimeca Dario, the General Counsel and Secretary of Precision BioSciences Inc., sale 9,833 shares at $2.06 during a trade that took place back on Jun 08, which means that Scimeca Dario is holding 32,514 shares at $20,256 based on the most recent closing price.

Stock Fundamentals for DTIL

Current profitability levels for the company are sitting at:

  • -34.11 for the present operating margin

The net margin for Precision BioSciences Inc. stands at -26.49. Equity return is now at value -44.20, with -18.90 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 4.50.